Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Quy Le, PhD, Thao T. Tang, Darcy Hamill, DO, Anilkumar Gopalakrishnapillai, PhD, Sonali Barwe, PhD MSc, Rhonda E. Ries, MA, Richard Aplenc, MD PhD, Andrew C. Wood, MD, E. Anders Kolb, MD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134821

Published: 2020

Journal Articles

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Anilkumar Gopalakrishnapillai, PhD, Colin Correnti, PhD, Anne Kisielewski, BS, Allison Kaeding, MD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 3925.

https://doi.org/10.1182/blood-2019-130941

Published: 2019

Journal Articles

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Ishnoor Sidhu, Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Kristi Lynn Kiick, PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 5010.

https://doi.org/10.1182/blood-2019-130949

Published: 2019

Journal Articles

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2738.

https://doi.org/10.1182/blood-2019-130934

Published: 2019

Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2683.

https://doi.org/10.1182/blood-2019-131050

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, PhD, Allison Kaeding, MD, Christoph Schatz, PhD, Anette Sommer, PhD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 1370.

https://doi.org/10.1182/blood-2019-123794

Published: 2019

Journal Articles

Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, PhD, Anne Kisielewski, BS, Ezio Bonvini, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 1387.

https://doi.org/10.1182/blood-2019-126791

Published: 2019

Journal Articles

Epigenetic Drug Combination Chemo-Sensitizes Pediatric AML By Reducing Cell Adhesion and Dislodging AML Cells from the Bone Marrow

Samantha Weber, BS, Anilkumar Gopalakrisnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2018) 132 (Supplement 1): 2637.

https://doi.org/10.1182/blood-2018-99-120321

Published: 2018

Journal Articles

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81

Anthony Quagliano, BS, Anilkumar Gopalakrisnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2018) 132 (Supplement 1): 3957.

https://doi.org/10.1182/blood-2018-99-120275

Published: 2018

Journal Articles

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia

Allison Kaeding, MD, Katherine Tarlock, MD, Sonali Barwe, PhD, Anilkumar Gopalakrisnapillai, PhD, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Rhonda E. Ries, MA, Laura Pardo, Cassie Chou, MD PhD, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 2641.

https://doi.org/10.1182/blood.V130.Suppl_1.2641.2641

Published: 2017

NARROW

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia

Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia

Epigenetic Drug Combination Chemo-Sensitizes Pediatric AML By Reducing Cell Adhesion and Dislodging AML Cells from the Bone Marrow

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81

Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only